-
Southern Medical Journal Apr 1988
Topics: Adult; Humans; Male; Orphenadrine; Substance-Related Disorders
PubMed: 3358186
DOI: 10.1097/00007611-198804000-00040 -
European Journal of Gastroenterology &... Aug 2020Many patients of liver cirrhosis are complaining of muscle cramps, which are annoying to them. There is no effective treatment for muscle cramps in cirrhotic patients... (Randomized Controlled Trial)
Randomized Controlled Trial
OBJECTIVE
Many patients of liver cirrhosis are complaining of muscle cramps, which are annoying to them. There is no effective treatment for muscle cramps in cirrhotic patients till now. This study purposed to evaluate efficacy and safety of orphenadrine in the treatment of muscle cramps in cirrhotic patients.
METHODS
One hundred and twenty four patients who had muscle cramps three or more times weekly were included. They were divided into two arms: 62 patients administrated orphenadrine and 62 administrated placebo. They were followed up till 2 weeks after the end of therapy. Muscle cramps were evaluated using questionnaire as regards severity, duration, and frequency. Also, side effects of orphenadrine were recorded.
RESULTS
Frequency, duration of muscle cramps, and pain score improved significantly after 1 month of orphenadrine therapy in comparison to placebo. Few side effects were recorded in the form of dry mouth, drowsiness, and nausea.
CONCLUSION
Orphenadrine is considered as promising safe drug for treatment of muscle cramps associated with liver cirrhosis.
Topics: Humans; Liver Cirrhosis; Muscle Cramp; Orphenadrine; Pain; Treatment Outcome
PubMed: 31834056
DOI: 10.1097/MEG.0000000000001622 -
The Journal of International Medical... 1991Orphenadrine citrate, a monomethylated derivative of diphenhydramine, has been used as a muscle relaxant and as an analgesic both alone or as a constituent of... (Comparative Study)
Comparative Study Review
Orphenadrine citrate, a monomethylated derivative of diphenhydramine, has been used as a muscle relaxant and as an analgesic both alone or as a constituent of combination products. Data on the efficacy of orphenadrine alone and in combination with paracetamol for painful conditions are evaluated in the present review. From the available animal data it is concluded that the antinociceptive effect of orphenadrine has been clearly demonstrated but data have also clearly indicated that it has muscle relaxant properties. Human placebo-controlled studies have shown some support for the view that orphenadrine on its own acts as a mild analgesic in painful conditions associated with muscle spasm. Although only a small number of well-controlled studies have been completed with the combination product of orphenadrine/paracetamol, each supports the view that the combination has superior efficacy over paracetamol alone. There is no doubt that the combination product is more efficacious than placebo.
Topics: Acetaminophen; Administration, Oral; Analgesics; Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Mice; Orphenadrine; Pain
PubMed: 1864455
DOI: 10.1177/030006059101900201 -
British Medical Journal Aug 1975
Topics: Adult; Epilepsy; Humans; Male; Orphenadrine; Substance-Related Disorders
PubMed: 1156831
DOI: 10.1136/bmj.3.5981.486 -
Acta Endocrinologica Nov 1977Studies were undertaken to elucidate whether orphenadrine influences thyroid function. Seven volunteers were given orphenadrine in weekly increasing dosage up to 300 mg...
Studies were undertaken to elucidate whether orphenadrine influences thyroid function. Seven volunteers were given orphenadrine in weekly increasing dosage up to 300 mg per day; in 5 patients chronically treated with 300 mg orphenadrine daily the drug was gradually discontinued. No changes were found in PBI, RT3U, TT3 and TSH during or after orphenadrine medication; also TSH- and TT3-responses to 200 microgram TRH iv were not influenced by the drug. Orphenadrine medication increased serum thyroxine values (P less than 0.001) as measured with the competitive protein binding (CPB) technique, but did not influence serum thyroxine values measured by radioimmunoassay. Orphenadrine added to serum in vitro in the Murphy-Pattee assay did not increase thyroxine values; two out of eight tested metabolites however did. It is concluded that orphenadrine in a dosage up to 300 mg per day does not influence thyroid function. It increases serum thyroxine levels as measured by the competitive protein binding technique of Murphy and Pattee. This is due to an in vitro competition between ethanol-extractable orphenadrine metabolites and thyroxine for binding sites on the thyroxine binding globulin.
Topics: Binding, Competitive; Humans; Male; Orphenadrine; Protein Binding; Thyroid Function Tests; Thyroid Gland; Thyroxine; Thyroxine-Binding Proteins
PubMed: 72472
DOI: 10.1530/acta.0.0860522 -
British Journal of Anaesthesia Oct 1968
Topics: Child, Preschool; Humans; Male; Orphenadrine; Positive-Pressure Respiration; Renal Dialysis; Tubocurarine
PubMed: 4880658
DOI: 10.1093/bja/40.10.789 -
Ugeskrift For Laeger Jan 1988
Clinical Trial Comparative Study Randomized Controlled Trial
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Orphenadrine; Pain, Postoperative; Premedication
PubMed: 3287725
DOI: No ID Found -
Wiener Klinische Wochenschrift Feb 2023Postoperative intravenous diclofenac reduces patient opioid demand and is commonly used in surgical units. Orphenadrine is mainly used in combination with diclofenac for... (Randomized Controlled Trial)
Randomized Controlled Trial
Intravenous diclofenac and orphenadrine for the treatment of postoperative pain after remifentanil-based anesthesia : A double-blinded, randomized, placebo-controlled study.
BACKGROUND
Postoperative intravenous diclofenac reduces patient opioid demand and is commonly used in surgical units. Orphenadrine is mainly used in combination with diclofenac for musculoskeletal injuries and postoperative pain control. The objective of this study was to compare the analgesic efficacy of diclofenac-orphenadrine, diclofenac alone and saline.
METHODS
We performed a double-blind, randomized, placebo-controlled, parallel-group, single-center clinical study investigating the opioid-sparing effect of a combination of diclofenac and orphenadrine versus diclofenac alone versus isotonic saline solution. Initially 72 patients were included and received total intravenous anesthesia during cruciate ligament surgery. All patients were postoperatively treated with a patient-controlled analgesia (PCA) device containing hydromorphone. Pharmacological safety was assessed by laboratory parameters, vital signs, and delirium detection scores.
RESULTS
There was no significant difference between the groups in cumulative dose of PCA analgesics required after 24 h postsurgery, with 5.90 mg (SD ± 2.90 mg) in the placebo group, 5.73 mg (SD ± 4.75 mg) in the diclofenac group, and 4.13 mg (SD ± 2.57 mg) in the diclofenac-orphenadrine group. Furthermore, there was no significant difference between the groups in cumulative dose of PCA analgesics required 2 h postsurgery (n = 65). Mean dose of hydromorphone required after 2 h was 1.54 mg (SD ± 0.57 mg) in the placebo group, 1.56 mg (SD ± 1.19 mg) in the diclofenac-only group, and 1.37 mg (SD ± 0.78 mg) in the diclofenac-orphenadrine group. However, when comparing the diclofenac-orphenadrine group and the diclofenac group combined to placebo there was a significant reduction in PCA usage in the first 24 h postsurgery. In total, there were 25 adverse events reported, none of which were rated as severe.
CONCLUSION
Orphenadrine-diclofenac failed to significantly reduce postoperative opioid requirements. However, in an exploratory post hoc analysis the diclofenac-orphenadrine and the diclofenac group combined versus placebo showed a tendency to reduce opioid demand in postoperative pain control. Further research is required to determine the value of orphenadrine as an adjuvant in a multimodal approach for postoperative pain management.
Topics: Humans; Diclofenac; Orphenadrine; Remifentanil; Analgesics, Opioid; Hydromorphone; Pain, Postoperative; Analgesics; Anesthesia; Double-Blind Method; Anti-Inflammatory Agents, Non-Steroidal
PubMed: 36576555
DOI: 10.1007/s00508-022-02131-x -
Journal of the American Medical... Jul 1958
Topics: Diphenhydramine; Orphenadrine
PubMed: 13563160
DOI: No ID Found